MYLAN-MINOCYCLINE 50 MG
MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) : 50 MG · DIN 02230735 · MYLAN PHARMACEUTICALS ULC
Health Canada status: CANCELLED POST MARKET
What is MYLAN-MINOCYCLINE?
MYLAN-MINOCYCLINE 50 MG contains MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02230735, held by MYLAN PHARMACEUTICALS ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Sep-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02230735 |
|---|---|
| Brand name | MYLAN-MINOCYCLINE |
| Generic / active ingredient | MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) : 50 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 50 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01AA08 MINOCYCLINE |
| AHFS class | 08:12.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Sep-2019 |
| Original market date | 1997-02-21 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J01AA08 MINOCYCLINE. 2 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MINOCYCLINE | 100 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 02084104 |
| MINOCYCLINE | 50 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 02084090 |
| AVA-MINOCYCLINE | 50 MG | CAPSULE | AVANSTRA INC | CANCELLED PRE MARKET | DIN 02363585 |
| DOM-MINOCYCLINE CAPSULES | 100 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239668 |
| DOM-MINOCYCLINE CAPSULES | 50 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239667 |
| ENCA 100MG | 100 MG | CAPSULE | PREMPHARM INC | CANCELLED POST MARKET | DIN 02248209 |
| ENCA 50MG | 50 MG | CAPSULE | PREMPHARM INC | CANCELLED POST MARKET | DIN 02248208 |
| MINOCIN | 100 MG | CAPSULE | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02173506 |
| MINOCIN | 50 MG | CAPSULE | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02173514 |
| MINOCIN CAP 100MG | 100 MG | CAPSULE | LEDERLE CYANAMID CANADA INC. | CANCELLED POST MARKET | DIN 00014591 |
Who else supplies MINOCYCLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MINOCYCLINE appears in 39 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.